title: [Therapy of hepatitis C: individualized approach to treatment].
abstract: About 70% of HCV infection fail to resolve spontaneously and progress to chronic hepatitis C, eventually to cirrhosis and HCC. Many studies have demonstrated that clinical manifestation and the outcome of HCV infection are negatively influenced by a variety of cofactors and comorbidities. Moreover many of these cofactors often reduce the chance of achieving a sustained virological response (SVR) with only available combination therapy with pegylated interferon-alpha2 (PEG-IFN) and ribavirine (RBV). Dose modification of both currently licensed drugs for treatment of HCV infection and variations of treatment duration are the most discussed strategies to optimized the therapy, particulary in patients infected by genotype 1 HCV. Tailoring the duration of peginterferon/ribavirine therapy to HCV kinetics is useful to optimize the results of therapy.
authors: Katedra i Klinika Chorób Zakaźnych, Chorób Watroby i Nabytych Niedoborów Odpornościowych Akademii Medycznej we Wrocławiu. krzysimon@gmail.com
authors: Krzysztof
authors: K
authors: Simon
authors: Monika
authors: M
authors: Pazgan-Simon
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D057285:Precision Medicine / Q000379:methods; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a